FDA Approves Blood Test That Can Identify Cancers Eligible for Targeted Therapies

FDA Approves Blood Test That Can Identify Cancers Eligible for Targeted Therapies
The U.S. Food and Drug Administration (FDA) has approved FoundationOne Liquid CDx, a blood test that can be used to identify cancer patients who may benefit from certain targeted therapies, including the FDA-approved prostate cancer therapy Rubraca (rucaparib). The test became commercially available on Aug. 28, and is covered by Medicare and Medicare Advantage for qualifying individuals across all solid tumors. "We believe that cancer patients and their physicians deserve the highest quality genomic testing to make informed decisions about personalized treatment," Brian Alexander, MD, chief medical officer at Foundation Medicine, which developed the test, said in a press release. Understanding the genetic profile of a tumor can provide useful data about prognoses, as well as indicate what treatments may or may not be appropriate. For instance, Rubraca is specifically approved for the treatment of
Subscribe or to access all post and page content.